Results 61 to 70 of about 1,618 (187)

Vitreous Inflammatory Cytokines and Chemokines, Not Altered After Preoperative Adjunctive Conbercept Injection, but Associated With Early Postoperative Macular Edema in Patients With Proliferative Diabetic Retinopathy

Frontiers in Physiology, 2022
PurposeTo investigate the influence of preoperative adjunctive anti-VEGF drug (Conbercept) on vitreous inflammatory cytokines and chemokines profiles and whether those cytokines were associated with early macular edema (ME) after surgery for patients ...
Hongyan Sun, Hongyan Sun, Wenjun Zou, Wenjun Zou, Zhengyu Zhang, Darui Huang, Darui Huang, Jinxiang Zhao, Jinxiang Zhao, Bing Qin, Ping Xie, Aime Mugisha, Qinghuai Liu, Zizhong Hu   +13 more
doaj   +1 more source

Conbercept and Retinal Photocoagulation in the treatment of Diabetic Macular Edema

Pakistan journal of medical sciences, 2019
To explore the clinical efficacy of intravitreal injection of conbercept in combination with retinal laser photocoagulation in the treatment of diabetic macular edema.Ninety patients with diabetic macular edema were selected and grouped into an observation group and a control group using random number table, 45 patients (45 eyes) each group.
Weizhe Meng, Ronghua Li, Xiufen Xie
openalex   +4 more sources

Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis

Clinical Interventions in Aging, 2017
Chunmei Cui, Hong Lu Department of Ophthalmology, Beijing Chao-Yang Hospital, Beijing, China Purpose: Conbercept is a new anti-vascular endothelial growth factor (VEGF) drug approved for the treatment of age-related macular degeneration (AMD). Although
Cui C, Lu H
doaj  

Recent Advancements in the Treatment of Age‐Related Macular Degeneration

Med Research, Volume 1, Issue 2, Page 151-169, September 2025.
ABSTRACT Age‐related macular degeneration (AMD) is a prevalent cause of visual impairment and blindness among the elderly. AMD can be categorized into two subtypes: “wet” and “dry.” Current treatments for wet AMD mainly involve anti‐vascular endothelial growth factor (VEGF) drugs, and there are three U.S.
Shan Liu, Danyang Lv, Junran Sun, Huixun Jia, Fang Zheng, Felipe Pereira, Siddharth Narendran, Zhenyu Dong, Haiyun Liu, Shunxiang Gao, Peirong Huang   +10 more
wiley   +1 more source

A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity

Scientific Reports, 2018
AbstractIntravitreal Conbercept (IVC) is the latest applied and effective treatment for the management of retinopathy of prematurity (ROP). However, conbercept escapes from the vitreous into the general circulation and reduce systemic VEGF concentrations.
Yong Cheng, Qingyu Meng, Dandan Linghu, Mingwei Zhao, Jianhong Liang   +4 more
openaire   +3 more sources

Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept [PDF]

International Journal of Retina and Vitreous, 2016
In the last few years, monoclonal antibodies have revolutionized the treatment of retinal neovascular diseases. More recently, a different class of drugs, fusion proteins, has provided an alternative treatment strategy with pharmacological differences.
João Rafael de Oliveira Dias, Gabriel Costa de Andrade, Eduardo Amorim Novais, Michel Eid Farah, Eduardo Büchele Rodrigues   +4 more
openaire   +2 more sources

Linking preclinical models to clinical realities: VEGF/VEGFR inhibitors and thrombotic microangiopathy in cancer therapy

iMetaOmics, Volume 2, Issue 2, June 2025.
This study investigates the risk of thrombotic microangiopathy (TMA) induced by vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) inhibitors in cancer therapy. Using data from the FDA Adverse Event Reporting System (FAERS), the WHO Global Database for Adverse Drug Reactions (Vigibase), and The Cancer ...
Aimin Jiang, Zhanzhi Li, Ying Liu, Junyi Shen, Quan Cheng, Anqi Lin, Peng Luo, Linhui Wang   +7 more
wiley   +1 more source

Intraocular Pharmacokinetics and Safety of Subretinal Injection Compared with Intravitreal Application of Conbercept in Vitrectomized Rabbit Eyes

Journal of Ophthalmology, 2020
Purpose. To evaluate the ocular pharmacokinetic properties of subretinal conbercept injection in vitrectomized rabbit eyes and to compare them with those by intravitreal injection. Methods.
Teng-teng Yao, Xiao-liang Jin, Yuan Yang, Yi-xiao Wang, Ya-li Zhou, Fang-lin He, Zhao-yang Wang   +6 more
doaj   +1 more source

Natural products targeting tumour angiogenesis

British Journal of Pharmacology, Volume 182, Issue 10, Page 2094-2136, May 2025.
Abstract Tumour angiogenesis is the formation of new blood vessels to support the growth of a tumour. This process is critical for tumour progression and metastasis, making it an attractive approach to cancer therapy. Natural products derived from plants, animals or microorganisms exert anti‐angiogenic properties and can be used to inhibit tumour ...
Xiaohua Lu, Lara Johanna Friedrich, Thomas Efferth   +2 more
wiley   +1 more source

Structural and Vascular Features of Macula Related to the Recurrence of Macular Edema in Central Retinal Vein Occlusion After Anti‐VEGF Therapy

Journal of Ophthalmology, Volume 2025, Issue 1, 2025.
Purpose: To identify the structural and vascular features of the macula related to the recurrence of macular edema (ME) in central retinal vein occlusion (CRVO) after intravitreal anti‐VEGF injections. Methods: This was a cross‐sectional study including CRVO patients without ME and age‐matched individuals.
Dazhuang Ren, Cece Zhao, Gaoxu Wei, Xiaoyun Hou, Chang Li, Zhiqing Li, Akio Oishi   +6 more
wiley   +1 more source